Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in shape sufficient to tolerate FCR therapy, should still be great candidates for the latter, Along with the benefit becoming that this cure may be finished in six months while ibrutinib need to be taken indefinitely. This fea